Immunotherapy in primary hormone-receptor positive breast cancer: A systematic review

IF 5.5 2区医学 Q1 HEMATOLOGY

Critical reviews in oncology/hematology Pub Date : 2025-05-20 DOI:10.1016/j.critrevonc.2025.104768

Maria-Theodora Melissari , Alkistis Papatheodoridi , Athanasios Argyriadis , Maria Kaparelou , Meletios Athanasios Dimopoulos , Flora Zagouri

{"title":"Immunotherapy in primary hormone-receptor positive breast cancer: A systematic review","authors":"Maria-Theodora Melissari , Alkistis Papatheodoridi , Athanasios Argyriadis , Maria Kaparelou , Meletios Athanasios Dimopoulos , Flora Zagouri","doi":"10.1016/j.critrevonc.2025.104768","DOIUrl":null,"url":null,"abstract":"<div><div>Hormone-receptor positive (HR+), HER2 negative breast cancer (BC) is considered immunologically silent, thus investigation of immunotherapy in this subtype has evolved slower. This systematic review offers an overview of the clinical trials investigating the safety and efficacy of ICI in primary HR+ /HER2- BC. Literature search was conducted up to October 30, 2022 to identify immunotherapy trials with checkpoint inhibitors in non-metastatic HR+ /HER2- breast cancer. 39 trials were identified, mainly in early-phase clinical trials. None of the trials investigate ICI monotherapy and only 2 Phase 3 clinical trials are ongoing. Most trials investigate the use of ICI in the neoadjuvant setting in combination with chemotherapy. 18 trials have reported results and 6 of them efficacy results specifically for HR+ /HER2- BC. ICI could be a promising therapeutic strategy for HR+ /HER2- BC, however clinical benefit is restricted to subgroups of patients, depending on tumor molecular profile.</div></div>","PeriodicalId":11358,"journal":{"name":"Critical reviews in oncology/hematology","volume":"212 ","pages":"Article 104768"},"PeriodicalIF":5.5000,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1040842825001568","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Hormone-receptor positive (HR+), HER2 negative breast cancer (BC) is considered immunologically silent, thus investigation of immunotherapy in this subtype has evolved slower. This systematic review offers an overview of the clinical trials investigating the safety and efficacy of ICI in primary HR+ /HER2- BC. Literature search was conducted up to October 30, 2022 to identify immunotherapy trials with checkpoint inhibitors in non-metastatic HR+ /HER2- breast cancer. 39 trials were identified, mainly in early-phase clinical trials. None of the trials investigate ICI monotherapy and only 2 Phase 3 clinical trials are ongoing. Most trials investigate the use of ICI in the neoadjuvant setting in combination with chemotherapy. 18 trials have reported results and 6 of them efficacy results specifically for HR+ /HER2- BC. ICI could be a promising therapeutic strategy for HR+ /HER2- BC, however clinical benefit is restricted to subgroups of patients, depending on tumor molecular profile.

查看原文本刊更多论文

免疫治疗原发性激素受体阳性乳腺癌：系统综述。

激素受体阳性（HR+）， HER2阴性乳腺癌（BC）被认为是免疫沉默的，因此对这种亚型的免疫治疗研究进展较慢。本系统综述综述了ICI治疗原发性HR+/HER2- BC的安全性和有效性的临床试验。文献检索进行到2022年10月30日，以确定使用检查点抑制剂治疗非转移性HR+/HER2-乳腺癌的免疫治疗试验。确定了39项试验，主要是早期临床试验。没有研究ICI单药治疗的试验，只有2个3期临床试验正在进行中。大多数试验调查了ICI在新辅助治疗中与化疗联合使用的情况。18项试验报告了结果，其中6项是针对HR+/HER2- BC的疗效结果。ICI可能是一种很有前景的治疗HR+/HER2- BC的策略，然而临床益处仅限于患者亚组，取决于肿瘤分子特征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical reviews in oncology/hematology 医学-血液学

CiteScore

11.00

自引率

3.20%

发文量

213

审稿时长

55 days

期刊介绍： Critical Reviews in Oncology/Hematology publishes scholarly, critical reviews in all fields of oncology and hematology written by experts from around the world. Critical Reviews in Oncology/Hematology is the Official Journal of the European School of Oncology (ESO) and the International Society of Liquid Biopsy.